Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib.
Carcinoma, Hepatocellular
/ drug therapy
Gallbladder
/ pathology
Gallbladder Diseases
/ chemically induced
Humans
Liver Neoplasms
/ drug therapy
Male
Middle Aged
Phenylurea Compounds
/ adverse effects
Protein Kinase Inhibitors
/ adverse effects
Quinolines
/ adverse effects
Rupture, Spontaneous
/ chemically induced
Tomography, X-Ray Computed
bone metastasis
gallbladder perforation
hepatocellular carcinoma
lenvatinib
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
01 Mar 2020
01 Mar 2020
Historique:
pubmed:
19
11
2019
medline:
15
9
2020
entrez:
19
11
2019
Statut:
ppublish
Résumé
A 59-year-old man who was receiving lenvatinib as a third-line tyrosine kinase inhibitor to treat hepatocellular carcinoma and multiple bone metastases complained of general fatigue four months after starting lenvatinib. A blood examination showed unexpectedly elevated serum C-reactive protein (CRP) levels. Computed tomography (CT) revealed rupture of the gallbladder wall, indicating gallbladder perforation. After conservative treatment, the patient received lenvatinib again under informed consent; however, one month later, CT revealed repeated rupture of the gallbladder wall. Gallbladder perforation had again been induced by lenvatinib. For this reason, lenvatinib is strongly considered a causative drug for gallbladder perforation.
Identifiants
pubmed: 31735795
doi: 10.2169/internalmedicine.3806-19
pmc: PMC7086315
doi:
Substances chimiques
Phenylurea Compounds
0
Protein Kinase Inhibitors
0
Quinolines
0
lenvatinib
EE083865G2
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
657-662Références
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Hepatol Res. 2019 Jan;49(1):111-117
pubmed: 30144256
ISRN Gastroenterol. 2011;2011:201529
pubmed: 21991498
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Cancer. 1954 May;7(3):462-503
pubmed: 13160935
J Thyroid Res. 2014;2014:638747
pubmed: 25295214
Clin Pract. 2014 Apr 30;4(1):635
pubmed: 24847435
Invest New Drugs. 2018 Apr;36(2):350-353
pubmed: 29018997
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Ann Surg Oncol. 2007 Jun;14(6):1860-9
pubmed: 17356952
Eur J Cancer. 2017 Aug;81:17-25
pubmed: 28591675
Best Pract Res Clin Haematol. 2009 Mar;22(1):115-28
pubmed: 19285278
Vasc Cell. 2014 Sep 06;6:18
pubmed: 25197551
Cancer. 2011 Oct 1;117(19):4475-83
pubmed: 21437884
World J Gastrointest Oncol. 2012 May 15;4(5):115-8
pubmed: 22645635
Cancer. 1983 Mar 1;51(5):863-77
pubmed: 6295617
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Hepatol Int. 2019 Mar;13(2):199-204
pubmed: 30671808
Pharmacotherapy. 2007 May;27(5):775-7
pubmed: 17461715
Clin Cancer Res. 2008 Sep 1;14(17):5459-65
pubmed: 18765537
Gastroenterology. 2006 Apr;130(4):1270-82
pubmed: 16618418
Clin Genitourin Cancer. 2009 Jan;7(1):62-3
pubmed: 19213671
J Gastroenterol Hepatol. 2005 Nov;20(11):1781-7
pubmed: 16246200
Ann Oncol. 2008 Mar;19(3):577-82
pubmed: 18024857